Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
03/2003
03/13/2003WO2003020710A1 Benzothiazepine derivatives
03/13/2003WO2003020700A2 SUBSTITUTED INDENO[1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF
03/13/2003WO2003020697A1 C2-disubstituted indane-1-ones and their derivatives, method for their production and their use as medicaments
03/13/2003WO2003020696A1 C2-substituted indane-1-ols and their derivatives, method for their production and their use as medicaments
03/13/2003WO2003020695A1 C2-disubstituted indane-1-ol systems, method for their production and their use as medicaments
03/13/2003WO2003020694A1 Derivatives of c2-substituted indan-1-ol systems, methods for the production thereof and their use as medicaments
03/13/2003WO2003020693A1 Polysubstituted indan-1-ol systems, method for the production and use thereof as drugs
03/13/2003WO2003020688A1 Selective protein tyrosine phosphatase inhibitors
03/13/2003WO2003020677A2 C2-substituted indane-1-ones and their derivatives, method for their production and their use as medicaments
03/13/2003WO2003020324A2 Methods for sterilizing preparations of digestive enzymes
03/13/2003WO2003020293A1 Health-care product for regulating blood glucose and its preparation method
03/13/2003WO2003020291A1 Increased solubility flavanolignan preparations
03/13/2003WO2003020283A2 Method for treating diabetic retinopathy
03/13/2003WO2003020282A1 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity
03/13/2003WO2003020275A1 Novel piperidin-2,6-dione bisulphate salts and their use for the treatment of stress-related affective disorders
03/13/2003WO2003020269A1 Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators
03/13/2003WO2003020265A2 Compositions comprising pectin and ascorbic acid
03/13/2003WO2003020263A1 Use of c2-substituted indane-1-ol systems for producing medicaments for the prophylaxis or treatment of obesity
03/13/2003WO2003020257A2 USE OF β-ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
03/13/2003WO2003020256A1 Use of c2-substituted indane-1-one systems for producing medicaments for the prophylaxis or treatment of obesity
03/13/2003WO2003020255A1 Use of polysubstituted indan-1-ol systems for producing drugs used in the prophylaxis or treatment of obesity
03/13/2003WO2003020217A2 Novel pyrazole analogs acting on cannabinoid receptors
03/13/2003WO2003020206A2 Use of atazanavir in hiv therapy
03/13/2003WO2003020201A2 Pre-mixes of glp-1 and basal insulin
03/13/2003WO2003020199A1 Use of derivatives of c2-substituted indan-1-ol systems for producing medicaments for the prophylaxis or the treatment of obesity
03/13/2003WO2003020026A1 Methods for treating disorders using plant extracts
03/13/2003WO2003004472A8 Arylamines for the treatment of conditions associated with gsk-3
03/13/2003WO2002100354A3 Pyrrolo[2,3-d]pyrimidine nucleoside analogs
03/13/2003WO2002095006A3 Muscle-specific expression vectors
03/13/2003WO2002094344A3 Method and apparatus for removal of insulin binding proteins (ibp) from biological fluids
03/13/2003WO2002089743A3 Use of compositions for treating rosacea
03/13/2003WO2002088080A3 Dual inhibitors of pde 7 and pde 4
03/13/2003WO2002087513A3 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
03/13/2003WO2002080850A3 Bulking agents as satiety agents
03/13/2003WO2002078625A3 Therapeutic combinations for cardiovascular and inflammatory indications
03/13/2003WO2002077217A3 Human dual specificity protein phosphatase 7-like protein
03/13/2003WO2002074343A3 The use of non-digestible polymeric foams to sequester ingested materials, thereby inhibiting their absorption by the body
03/13/2003WO2002074291A3 Compositions useful for the treatment of pathologies responding to the activation of ppar-gamma receptor
03/13/2003WO2002072543A3 Rxr activating molecules
03/13/2003WO2002068388A3 Acylated piperidine derivatives as melanocortin-4 receptor agonists
03/13/2003WO2002068015A3 Modular infusion device and method
03/13/2003WO2002067760A3 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
03/13/2003WO2002066427A3 (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions and uses thereof
03/13/2003WO2002060466A3 Gssp3 polynucleotides and polypeptides and uses thereof
03/13/2003WO2002058696A3 The use of substituted azetidinone compounds for the treatment of sitosterolemia
03/13/2003WO2002053519A3 Hydrophobic polyamine analogs and methods for their use
03/13/2003WO2002050019A3 Diamines as modulators of chemokine receptor activity
03/13/2003WO2002043763A3 Combination of gaba agonists and aldose reductase inhibitors
03/13/2003WO2002043762A3 Combination of gaba agonists and sorbitol dehydrogenase inhibitors
03/13/2003WO2002042332A3 Truncated cd200
03/13/2003WO2002038140A3 Therapeutic uses for ip3 receptor-mediated calcium channel modulators
03/13/2003WO2002032411A3 Combination of statins and sorbitol dehydrogenase inhibitors
03/13/2003WO2002024194A3 Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
03/13/2003WO2002022151A3 Use of glp-1 and flp-2 peptides for treatment of bone disorders
03/13/2003WO2002017949A3 Novel functions for dp214
03/13/2003WO2002013797A3 Therapeutic combination of a cetp inhibitor and atorvastatin
03/13/2003WO2002011708A3 Methods for inducing apolipoprotein e secretion
03/13/2003WO2002008401A3 Elongase genes and uses thereof
03/13/2003WO2001082911A3 TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING CLIOQUINOL
03/13/2003US20030050461 Protein for use in the diagnosis, prevention and treatment of metabolic, developmental, nutrient transport and cell proliferation disorders
03/13/2003US20030050460 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of cardiovascular and bone disorders
03/13/2003US20030050344 Thyroid hormones or their salts in capsule or in swallowable uniform soft-gel gelatin matrices for treatment of hypothyroidism
03/13/2003US20030050332 Modifications of the trometamol salt of R-thioctic acid as well as a process for their production
03/13/2003US20030050318 Stable water in oil aminophylline emulsions
03/13/2003US20030050310 Hydroxamic acid derivatives as proteinase inhibitors
03/13/2003US20030050309 A gelatinase inhibitor for modulating the activity of a dopamine, serotonin, or norepinephrine receptor or transporter
03/13/2003US20030050304 Therapeutic compounds
03/13/2003US20030050301 A drug mixture additionally comprising an antihypertensive agent or it's prodrug and a carrier, vehicle or diluent
03/13/2003US20030050300 Therapeutic 5-HT ligand compounds
03/13/2003US20030050294 Controlled release formulation for preventing or treating risk factors for cardiovascular disease
03/13/2003US20030050272 Purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase nucleic acids and polypeptides
03/13/2003US20030050250 Administering an aromatic dipeptide derivative with a chemotherapeutic agent to treat tumor metastasis, solid tumor growth, angiogenesis and other neoplasia diseases
03/13/2003US20030050234 Conotoxin peptide extracted from the venom of a marine snail, Conus magnus (cono=cone); disorders associated with voltage gated sodium ion channel; neuromuscular blocking agents; local anesthetics; neuroprotective agents; analgesics
03/13/2003US20030050228 Administering by mouth an effective amount of an insulin polypeptide derivative within one hour of ingestion of a meal by the patient to provide an insulin drug concentration in portal vein blood of 10-1,000 U/ml within 60 minutes
03/13/2003US20030049865 Microfabricated devices for the storage and selective exposure of chemicals and devices
03/13/2003US20030049823 eNOS mutations useful for gene therapy and therapeutic screening
03/13/2003US20030049643 G protein-coupled receptors for use in the treatment of cardiovascular, nervous system, angina pectoris, inflamatory bowel, allergies and gastrointestinal disorders
03/13/2003US20030049365 Solvent extraction of fruit skins using acetone, ethanol
03/13/2003US20030049337 Using eucalyptus plant extract
03/13/2003US20030049279 Polysaccharide encapsualted antigen
03/13/2003US20030049245 Methods for sterilizing preparations of digestive enzymes
03/13/2003US20030049226 Methods of treating syndrome x with aliphatic polyamines
03/13/2003US20030049211 Remedies and preventives for dental diseases
03/13/2003US20030049208 For delivering a medicant; product includes a coating having a medicament or agent; bioavailabilty; chewing gum product that releases caffiene for improved performance
03/13/2003CA2459937A1 Ncam binding compounds
03/13/2003CA2459346A1 Benzothiazepine derivatives
03/13/2003CA2459136A1 A caspase-8 binding protein, its preparation and use
03/13/2003CA2459045A1 Antidiabetic extracts of artemisia dracunculus
03/13/2003CA2458963A1 Increased solubility flavanolignan preparations
03/13/2003CA2458876A1 Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
03/13/2003CA2458807A1 Use of atazanavir in hiv therapy
03/13/2003CA2458555A1 Use of c2-substituted indane-1-one systems for producing medicaments for the prophylaxis or treatment of obesity
03/13/2003CA2458553A1 Use of polysubstituted indan-1-ol systems for producing drugs used in the prophylaxis or treatment of obesity
03/13/2003CA2458552A1 Use of derivatives of c2-substituted indan-1-ol systems for producing medicaments for the prophylaxis or the treatment of obesity
03/13/2003CA2458527A1 C2-substituted indane-1-ols and their derivatives, method for their production and their use as medicaments
03/13/2003CA2458526A1 Use of c2-substituted indane-1-ol systems for producing medicaments for the prophylaxis or treatment of obesity
03/13/2003CA2458523A1 C2-disubstituted indane-1-ol systems, method for their production and their use as medicaments
03/13/2003CA2458521A1 Derivatives of c2-substituted indan-1-ol systems, methods for the production thereof and their use as medicaments
03/13/2003CA2458213A1 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity
03/13/2003CA2457922A1 Novel pyrazole analogs acting on cannabinoid receptors
1 ... 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 ... 1298